EZH2 (9B6) Monoclonal Antibody

$Lane 1: 293T Cells; Lane 2: 293 Cells; Probed with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: 293T Cells; Lane 2: 293 Cells; Probed with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human colon cancer tissue incubated with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human colon cancer tissue incubated with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with EZH2 (9B6) Monoclonal Antibody (bsm-52743R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P
IF(ICC)
IHC

Reactivity

Human

Overview
Catalog #	bsm-52743R
Product Name	EZH2 (9B6) Monoclonal Antibody
Applications	WB, IHC-P, IF(ICC), IHC
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human EZH2 between 350 to 450 amino acids
Clonality	Monoclonal
Clone #	9B6
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	2146
Swiss Prot	Q15910
Synonyms	Histone-lysine N-methyltransferase EZH2, ENX-1, Enhancer of zeste homolog 2, Lysine N-methyltransferase 6, EZH2
Background	Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC